Cargando…

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV

The integrase strand transfer inhibitors (INSTIs) are the newest antiretroviral class in the HIV treatment armamentarium. Dolutegravir (DTG) is the only second-generation INSTI with FDA approval (2013). It has potential advantages in comparison to first-generation INSTI’s, including unboosted daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dow, Dorothy E., Bartlett, John A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269626/ https://www.ncbi.nlm.nih.gov/pubmed/25134686 http://dx.doi.org/10.1007/s40121-014-0029-7

Ejemplares similares

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
por: Zhao, Alexa Vyain, et al.
Publicado: (2022)

A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants
por: Sayyed, Sharif Karim, et al.
Publicado: (2023)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

1043. The impact of integrase strand transfer inhibitors (InSTIs) on weight gain among adults with HIV in clinical care
por: Thatipelli, Sneha, et al.
Publicado: (2020)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
por: Murray, Milena M, et al.
Publicado: (2023)

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
por: Abdullahi, Adam, et al.
Publicado: (2023)

106. META-INSTI: Metabolic Adverse Events Following Integrase Strand Transfer Inhibitor Administration in Spontaneous Adverse Event Reports
por: Murray, Milena M, et al.
Publicado: (2020)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
por: Barski, Michał S., et al.
Publicado: (2019)

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
por: Monroe, Anne K, et al.
Publicado: (2019)

Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
por: Henerico, Shimba, et al.
Publicado: (2022)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
por: Foster, Emma G., et al.
Publicado: (2022)

Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol
por: Mulindwa, Frank, et al.
Publicado: (2022)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2017)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
por: Smith, Steven J., et al.
Publicado: (2021)

Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir
por: Mahajan, Pankaj S., et al.
Publicado: (2023)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
por: Foster, Emma G., et al.
Publicado: (2023)

Integrase strand-transfer inhibitors for treatment of early HIV infection: A case series
por: Teira, Ramón, et al.
Publicado: (2019)

Impact of HIV infection and integrase strand transfer inhibitors-based treatment on the gut virome
por: Villoslada-Blanco, Pablo, et al.
Publicado: (2022)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey
por: Cecchini, Diego M., et al.
Publicado: (2019)

Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK
por: Mbisa, Jean L, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of integrase strand transfer inhibitors
por: Lu, Chi-Hua, et al.
Publicado: (2021)

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
por: Abram, Michael E., et al.
Publicado: (2017)

Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs
por: Kirichenko, Alina, et al.
Publicado: (2020)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_62qk7mdl2bbfqan1phglna49tg